Q-omics provides the consensus-scored H2BC14 profile across patient tissues and cancer cell-line models. H2BC14 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, H2BC14 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, H2BC14 RNA expression shows 13,388 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where H2BC14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC14 survival associations across molecular data types. H2BC14 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC14 RNA expression–survival associations across cancer types. High H2BC14 expression shows unfavorable associations in KIRC, ACC, KIRP, PAAD, LGG and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for H2BC14 RNA expression.
This table summarizes H2BC14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BC14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC14 shows higher tumor expression in HNSC, UCEC, KIRC, LUSC, STAD and BRCA. The HNSC box plot shows higher H2BC14 RNA expression in tumor versus normal tissue (log2 FC = +0.633, t-test p < 0.001).
This table shows molecular features associated with H2BC14 in patient tissues and cancer cell lines. In patient samples, H2BC14 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, H2BC14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
